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Background. Several models have been developed to predict the risk of mortality in community-acquired pneumonia (CAP). This
study aims to systematically identify and evaluate the performance of published risk prediction models for CAP. Methods. We
searched MEDLINE, EMBASE, and Cochrane library in November 2011 for initial derivation and validation studies for models
which predict pneumonia mortality. We aimed to present the comparative usefulness of their mortality prediction. Results. We
identified 20 different published risk prediction models for mortality in CAP. Four models relied on clinical variables that could be
assessed in community settings, with the two validated models BTS1 and CRB-65 showing fairly similar balanced accuracy levels
(0.77 and 0.72, resp.), while CRB-65 had AUROC of 0.78. Nine models required laboratory tests in addition to clinical variables,
and the best performance levels amongst the validatedmodels were those of CURB and CURB-65 (balanced accuracy 0.73 and 0.71,
resp.), with CURB-65 having an AUROC of 0.79. The PSI (AUROC 0.82) was the only validated model with good discriminative
ability among the four that relied on clinical, laboratorial, and radiological variables. Conclusions. There is no convincing evidence
that other risk prediction models improve upon the well-established CURB-65 and PSI models.
1. Introduction
Community-acquired pneumonia (CAP) is common and
associated with significant mortality [1–3]. Severity assess-
ment is an important step in the management of CAP [4–
6] because the early identification of individuals at high
risk of death may help in deciding the site of care and the
intensity ofmanagement [7]. Furthermore, subjective clinical
judgment can underestimate pneumonia severity [8], and this
may result in under-treatment and poor outcomes [9, 10].
Therefore, CAP risk prediction models have been developed
to help clinicians predict pneumonia outcome and determine
appropriate management more accurately.
The most widely known, well-validated, and commonly
used risk predictionmodels are CURB-65 [3] and Pneumonia
severity index (PSI) [11]. Recent systematic reviews have
focused on assessing the comparative performance of these
models [12, 13]. However, many other models have been
developed, some of which are designed to predict mortality
[14, 15], while others also include the need for ventilatory and
vasopressor support [16–18]. The diverse and ever-increasing
range of models may pose difficulties for clinicians who are
attempting to choose a tool for use in their daily practice. To
date, there has yet to be a clear consensus on the model that
should be used [19], andno systematic attempt to compare the
key characteristics and usefulness of the existing pneumonia
scores has been made.
In this systematic review, we provide a comprehensive
and up-to-date overview of the existing published risk pre-
diction models for mortality in community-acquired pneu-
monia. We did not include scores which were designed to
predict ventilatory and vasopressor support because of the
inconsistency in decisions to provide these therapies depend-
ing on treatment site. We also aim to summarize the key
features of each model such as variables used, risk stratifica-
tion, and the comparative performance in terms of sensitivity,
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specificity, balanced accuracy, and area under the curve
(AUC) values so that practitioners can make an informed
choice.
2. Methods
2.1. Eligibility Criteria. We selected studies that were the
first to report the derivation or validation of each risk
prediction model for predicting mortality in CAP. There
was no restriction on the type of study (prospective or
retrospective) or country of origin. For pragmatic reason, we
excluded studies that aimed to carry out further testing of
risk models systems that had already been validated once and
reported, as there are several validation studies for commonly
used scores such as PSI and CURB-65. In such instances, we
have used pooled data from published meta-analyses where
available [12, 13]. Derivation studies were defined as studies
which first reported the prognostic score. Validation studies
were defined as studies which first tested the performance of
a derived score in a separate cohort.
2.2. Search Strategy. We searched MEDLINE, EMBASE,
and Cochrane Central Register of Controlled Trials with
no date limitations in November 2011 using the search
terms listed in Supplementary Material 1 available online at
http://dx.doi.org/10.1155/2013/504136, without any language
restriction. We also checked the bibliographies of included
studies and recent review articles for relevant studies.
2.3. Study Selection and Data Extraction. Two reviewers
(Chun Shing Kwok, Kenneth Woo) scanned all titles and
abstracts to select studies that met the inclusion criteria.
Full reports (where available) of potentially relevant studies
were retrieved and independently checked by the other two
reviewers (YoonK. Loke, PhyoKyawMyint).Where therewas
any uncertainty or discrepancies, the article was discussed
among the reviewers to determine if the studies should
be included. We also contacted authors if there were any
areas that required clarification. Data were collected using
a standardized form by two authors independently (Chun
Shing Kwok, Kenneth Woo), and this was checked by Yoon
K. Loke. Data were collected on score name, setting for
score application, year of study, country of origin, participant
selection criteria, methodology for diagnosis of pneumonia,
outcomes assessed, definition of severe pneumonia, partici-
pant characteristics, lost to followup in study, and the results.
Data relating to studymethodologywere also collected for the
quality assessment such as risk of confounding and statistical
methods.The primarymeasure of interest was the area under
the receiver operating curve (AUROC) as this reflects the
overall discriminant ability of the risk prediction model;
where this was not reported, we calculated balanced accuracy
based on the following equation (sensitivity plus specificity)
divided by two.
We also extracted results of existing meta-analyses on
pneumonia risk prediction models [12, 13] to address the fact
that both PSI andCURB-65 have been validated several times
over, and we intended to present only the pooled data.
2.4. Assessment of Study Validity. Quality assessment was
performed by Chun Shing Kwok using a methodological
checklist for prognostic studies from the National Institute
for Heath and Clinical Excellence [20]. Briefly, the checklist
contains six components including study sample represen-
tative of population of interest, loss to followup unrelated
to key characteristics, prognostic factor of interest, outcome
of interest, potential confounders accounted for, and the
appropriateness of statistical analysis.
2.5. Data Analysis. Due to the nature of this systematic
review, we did not intend to conduct meta-analysis but
planned to summarize the main findings descriptively in
tables and figures. In particular, we evaluated key perfor-
mance parameters (AUROC, balanced accuracy, sensitivity
and specificity) for each scoring system and depicted this
graphically according to the frequency of variables required
for the calculation of the score. For these plots, we used
validation study or meta-analysis results where available. We
conducted additional subgroup analysis restricted to studies
that used prospectively collected datasets, which may poten-
tially be of greater validity than retrospective evaluations.
3. Results
From the 1,947 titles and abstracts, 93 articles were selected
for detailed review (Figure 1). Of these, 20 different risk pre-
diction models for mortality in pneumonia were described
in 18 documents (including abstracts-only publications)
between 1987 and 2011 (Figure 1) [6–8, 11, 14, 15, 21–32]. The
list of excluded studies is shown in SupplementaryMaterial 2.
The detailed characteristics of studies and the description of
individual models are shown in Table 1 and Supplementary
Material 3, respectively. Aside from two [24, 28], all studies
were conducted in emergency department settings. Diverse
combinations of variables including patient characteristics,
clinical features, laboratory results, radiological findings and
physician judgments were considered across these models.
Two studies used ICD-9 codes [11, 25] and one used ICD-10
codes to confirm pneumonia diagnosis [31]. One study [29]
did not provide a formal definition as to how pneumonia was
diagnosed.
3.1. Quality Assessment of Models. Study validity is summa-
rized in Supplementary Material 4. One major limitation is
that only 14 of the risk predictionmodels had validation data,
whereas 6 reported findings from derivation studies (SOAR,
AFSS, PARB, PIRO, CARSI, and CARASI) without further
validation [24, 25, 28, 29, 32]. All studies had a study sample
that appeared representative of the population of interest,
with adequately defined outcomes. Mortality was the main
outcome of interest in all but one study where a 30-day
mortality and the need for oxygen therapy were combined
[29]. The extent of lost to followup or missing data was
unclear in the analysis for nine models (BTS 1, 2, 3, CURB,
IDSA/ATS 2007, mATS, SOAR, A-DROP, and PARB) [6, 15,
22–24, 26, 29]. The impact of potential confounding factors
was unclear in many studies, whereas eleven models (BTS 1,
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EMBASE results: 879 
potential abstracts
MEDLINE results: 768 
potential abstracts
93 full articles were reviewed 
for inclusion
75 articles were excluded because 
they were not
(1) derivation studies 
(2) initial validation studies
18 articles were included in review which 
evaluated 20 pneumonia scores
Figure 1: Search results and study selection.
2, 3, CURB, CURB-65, CRB-65, MRI, PSI, SOAR, AFSS, and
PARB) [11, 14, 21–25, 29] used appropriate statistical methods
(i.e., use of logistic regressionmodels or statisticalmethods to
choose factors that were most predictive of mortality) for the
derivation of the prognostic score. Where statistical methods
were not used to identify variables in the derivation of the
models, some models were derived based on the hypothesis
that certain variables may be correlated with death (e.g.,
shock index), while othermodels tested scores proposed from
guidelines (e.g., ATS scores). One study was only available in
the abstract form [29].
3.2. Variables Used in Risk Prediction Models. The frequency
of variables which were used more than once in the models
and their occurrence in individual scores is shown in Table 2.
Variables were categorized into five groups: patient character-
istics (age, gender, immunosuppression, and renal disease),
clinical variables (pulse rate, blood pressure, respiratory rate,
temperature, presence of shock, and confusion), laboratory
measures (urea/blood urea nitrogen (BUN), white cell count,
PaO
2
/SaO
2
, hematocrit, glucose, sodium, and pH), radiolog-
ical findings (pleural effusion and multilobar pneumonia on
chest X-ray), and physician judgment (need for mechanical
ventilation). The four most commonly used variables (found
in >10 scores) were confusion or altered mental status,
respiratory rate, systolic blood pressure, and urea.
Some of the risk prediction models also required
more complex concepts involving clinical interpretation and
decision-making or even the results of other severity predic-
tion tools. The MRI score included the Glasgow coma score,
judgment on underlying ultimately or rapidly fatal illness,
simplified acute physiology score, acute organ system failure,
and ineffective initial antimicrobial treatment. The modified
ATS score had major criteria of requirement for mechanical
ventilation or septic shock, and the IDSA/ATS 2007 score
included receipt of invasivemechanical ventilation and septic
shock and the need for vasopressors. These models were
therefore considered separately.
3.3. Risk Prediction Model Evaluation and Derivation and
Validation Results. The results from the included derivation
and validation studies are shown in Table 3. Supplementary
Material 2 describes the individual severity scores according
to the year of publication in chronological order.
3.4. Risk Prediction Models Using Only Clinical Variables.
Four scores (BTS 1, CRB-65, CARSI, and CARASI) [21, 22,
32] were based on simple clinical measures that could be
measured on first presentation in the community, with no
requirement for laboratory or radiological testing. All were
derived in the UK between 1987 and 2011. The number of
variables ranged from three to six and respiratory rate was
included in all scores. Of the two validated models, BTS1
and CRB-65 had fairly similar balanced accuracies (0.77 and
0.72 resp.), while CRB-65 was shown in the meta-analysis to
have an AUROC of 0.78. Neither CARSI nor CARASI had
been validated but the derivation studies had relatively low
balanced accuracy (0.64) or AUROC (0.64) for both models.
3.5. Risk Prediction Models Using Both Clinical Variables and
Laboratory Testing. Nine prognostic models (BTS2, BTS3,
CURB, CURB-65, A-DROP, CURB-age, SOAR, CURSI,
CURASI) [21–24, 26, 31] were constructed using both clinical
and laboratory parameters. They were developed in the UK
between 1987 and 2010, except for A-DROP which was
proposed by the Japanese Respiratory Society. All models
were externally validated except for SOAR [24]. The number
of variables ranged from three to six, and, respiratory rate was
included in all models. Other commonly included variables
were confusion and urea/blood urea nitrogen. CURB and
CURB-65 had the best balanced accuracy (0.73 and 0.71,
resp.). Here, AUROC was seldom reported amongst the
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Table 1: Characteristics of derivation and validation studies which predict pneumonia mortality.
Paper Score Design Setting Year Country Inclusion CAP diagnosis Mortalityoutcome
BTS 1987
[22]
(derivation)
British
Thoracic
Society
Score 1, 2, 3
Prospective Hospital
November
1982 to
December
1983
UK
Adults aged 15–74
years with
pneumonia
Acute illness with
radiological pulmonary
shadowing which was
neither preexisting nor
of another known cause.
Mortality
Farr et al.
1991 [23]
(validation)
British
Thoracic
Society
Score 1, 2, 3
Retrospective Hospital
January
1984 to
1986
United
States
Adults aged from 15
to 80 years with the
diagnosis of
pneumonia
Acute respiratory illness
contracted in the
community and
accompanied by a new
radiographic infiltrate
Mortality
Leroy et al.
1996 [14]
Mortality
risk index
Combined
retrospective
and
prospective
ICU
Derivation
January
1987–
December
1992.
Validation
January
1993–
December
1994
France
Adult patients aged
>16 admitted to the
intensive care and
infectious disease
unit with the
diagnosis of CAP
Admission from home
or a nursing home with
the presence of
pulmonary infiltrate on
CXR and acute onset of
clinical features of
pneumonia
Mortality
in ICU
Neill et al.
1996 [8] CURB Prospective Hospital
July 1992
to 1993
New
Zealand
Adults with
pneumonia without
severe
immunosuppression
Acute illness
radiographic pulmonary
shadowing with neither
preexisting nor another
known cause
Mortality
Fine et al.
1997 [11]
Pneumonia
severity
index
Prospective
Hospital
(inpatients
and
outpatients)
1989,
1991–1993
United
States and
Canada
Adults aged >18
years with diagnosis
of pneumonia
ICD-9-CM diagnosis of
pneumonia
30-day
mortality
Lim et al.
2003 [21]
CURB-65,
CRB-65
Retrospective
analysis of
prospectively
collected
data
Hospital 1998–2000
UK, New
Zealand,
andThe
Netherlands
Adults with CAP
Acute respiratory tract
illness associated with
radiographic shadowing
on an admission chest
radiograph
30-day
mortality
Ewig et al.
2004 [15]
Modified
American
Thoracic
Society Rule
Prospective Hospital
June
1998–May
2001
Spain
All patients
presenting with CAP
in a university
hospital between
June 1998 and May
2001
New pulmonary
infiltrate with symptoms
and signs of a lower
respiratory tract
infection
30-day
mortality
Myint et al.
2006 [24] SOAR Prospective Hospital NA UK
Clinical features of
pneumonia and new
CXR shadow
Clinical features of
pneumonia and new
CXR shadow
42-day
mortality
Myint et al.
2007 [27]
(derivation)
CURB age Prospective Hospital NA UK
Clinical features of
pneumonia and new
CXR shadow
Clinical features of
pneumonia and new
CXR shadow
42-day
mortality
Escobar et
al. 2008 [25]
Abbreviated
Fine Score Retrospective Hospital
2000–
2002,
2004-2005
United
States
All nonobstetric,
nonpsychiatric
patients aged >18
years with
pneumonia
ICD codes defined by
Fine et al
30-day
mortality
Shindo et
al. 2008
[26]
A-DROP Retrospective Hospital
November
2005–
January
2007
Japan Patients with CAP
Pneumonia in a patient
who was not
hospitalized and who
was carrying on with
activities of daily living
30-day
mortality
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Table 1: Continued.
Paper Score Design Setting Year Country Inclusion CAP diagnosis Mortalityoutcome
Myint et al.
2009 [7]
(validation)
CURB age Prospective Hospital 2006–2008 UK Patients with CAP
Acute illness with
clinical features of lower
respiratory tract
infection characterized
by new radiographic
shadowing
30-day
mortality
Myint et al.
2009 [31]
(derivation)
CURSI
CURASI Retrospective Hospital
September
2004 to
July 2005
UK Patients with CAP ICD-10 codes diagnosisof pneumonia
Inpatient
mortality
Rello et al.
2009 [28] PIRO score Prospective ICU NA Spain
Patients aged >18
years with
pneumonia
Pneumonia confirmed
by CXR and clinical
findings
28-day
mortality
Liapikou et
al. 2009 [6]
IDSA/ATS
2007 Prospective Hospital
January
2000–
2007
Spain
Patients aged >15
years who were
admitted to the
emergency
department for CAP
in a university
hospital from
January 2000
through 2007
New pulmonary
infiltrate on admission
chest radiograph and
symptoms and signs of
lower respiratory tract
infection
30-day
mortality
Uchiyama
et al. 2010
[29]
PARB Retrospective Hospital
March
2006 to
November
2008
Japan Adult patients withCAP Unclear
30-day
mortality
or needing
>2 weeks
of oxygen
therapy
Myint et al.
2010 [30]
(validation)
CURSI,
CURASI Prospective Hospital
2006–
2008 UK
Clinical features of
pneumonia and new
CXR shadow
Clinical features of
pneumonia and new
CXR shadow
42-day
mortality
Musonda et
al. 2011 [32]
CARSI,
CARASI Prospective Hospital 2008 UK
Patients with clinical
and radiological
features of CAP from
3 hospitals in the UK
Clinical features of
pneumonia (cough,
sputum, and shortness of
breath, with or without
fever) and new CXR
shadow
30-day
mortality
ICU: intensive care unit; CXR: chest X-ray; CAP: community-acquired pneumonia.
modes but bothCURB-65 (AUROC0.79 frommeta-analysis)
and A-DROP (AUROC 0.85) showed reasonable discrimina-
tive ability.WhileA-DROPappears to have superiorAUROC,
we noted important quality issues regarding the absence of
followup for vital status within the study (Supplementary
Material 3) and lack of generalizability due to it being a
retrospective, single-centre study of hospitalized patients.
3.6. Risk Prediction Models Using Clinical, Laboratorial, and
Radiological Findings. Four models (PSI, AFSS, PIRO, and
PARB) [11, 25, 28, 29] required radiological finding in their
scoring system. These models were developed in the US,
France, Spain, and Japan between 1996 and 2010; the number
of variables ranged from four to twenty in these models [11].
The PSI is the only validated model here, with an AUROC of
0.82 in the meta-analysis. The performance of these models
from derivation studies ranged from an AUROC of 0.75 for
AFSS to 0.88 for the PIRO score.
3.7. Risk Prediction Models That Require Additional Clinical
Decisions. Three models (MRI, mATS, and IDSA/ATS 2007)
[6, 14, 15] gave weighting to clinical judgment, for example,
that initial antimicrobial therapy was ineffective or that
vasopressor therapy was needed for septic shock. These
validatedmodelswere originated from theUS andFrance and
were principally designed for the prognostic use in intensive
care settings or pneumonia cases that may need to be triaged
to intensive care. The best performance here was achieved by
the modified ATS score with a balanced accuracy of 0.94.
3.8. Summary of the Performance of Risk Prediction Models
according to Number of Variables. The comparative perfor-
mance of the risk prediction models according to number
of prognostic variables is summarized graphically in Figure 2
(balanced accuracy and AUC) and Figure 3 (sensitivity and
specificity). Of the validated measures that are suitable for
general clinical use, the CURB derivatives and PSI had the
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Table 3: Results of derivation and validation studies for pneumonia severity scores.
Paper Score Patients Age % male Lost to followup Results
BTS 1987
[22]
(derivation)
British
Thoracic
Society
Score 1, 2, 3
511 patients 48.4 60.5 28 lost tofollowup
Derivation:
Score 1 (URB): 87.5% sensitivity, 78.7% specificity
Score 2 (CRB): 39.1% sensitivity, 93.9% specificity
Score 3 (COUW): 50% sensitivity, 89% specificity
Farr et al.
1991 [23]
(validation)
British
Thoracic
Society
Score 1, 2, 3
245 patients 58.9 55 None
Validation:
Score 1 (URB): 70% sensitivity, 84.2% specificity,
28.6% PPV, 96.9% NPV, 82.3% overall accuracy
Score 2 (CRB): 35% sensitivity, 88.5% specificity,
21.9% PPV, 93.7% NPV, 84% overall accuracy
Score 3 (COUW): 42.1% sensitivity, 86.6%
specificity, 24.2% PPV, 93.6% NPV, 82.4% overall
accuracy
Leroy et al.
1996 [14]
Mortality
risk index
460 patients, 335
derivation, 125
validation
62.5 64.3 None
Derivation: 62% sensitivity, 92% specificity, 74%
PPV
Validation: 61% sensitivity, 98% specificity, 92%
PPV
Neill et al.
1996 [8] CURB 255 patients 58 55
6 patients, no
consent was
obtained
Derivation:
CURB: 95% sensitivity, 91% specificity, 22% PPV,
99% NPV
BTS 1: 90% sensitivity, 76% specificity, 25% PPV,
99% NPV
BTS 2: 65% sensitivity, 88% specificity, 33% PPV,
97% NPV
BTS 3: 63% sensitivity, 88% specificity, 32% PPV,
97% NPV
Fine et al.
1997 [11]
Pneumonia
severity
index
14199 derivation,
38039 validation NA 51 None
Derivation: PSI area ROC 0.84
Validation: PSI area ROC: MedisGroup cohort
0.83, PORT cohort 0.89
Lim et al.
2003 [21]
CURB-65,
CRB-65 1068 patients 64 51.5 None
Derivation:
CURB (>2): 75.4% sensitivity, 68.9% specificity,
20.5% PPV, 96.3% NPV
CURB-65 (>3): 68.1% sensitivity, 74.9% specificity,
22.4% PPV, 95.7% NPV
CRB-65 (>2): 76.8% sensitivity, 64.3% specificity,
18.6% PPV, 96.3% NPV
Validation:
CURB (>2): 75% sensitivity, 70.1% specificity,
20.5% PPV, 96.5% NPV
CURB-65 (>3): 75% sensitivity, 74.7% specificity,
23.4% PPV, 96.7% NPV
CRB-65 (>2): 80% sensitivity, 61.3% specificity,
17.6% PPV, 96.7% NPV
Ewig et al.
2004 [15]
Modified
American
Thoracic
Society Rule
696 patients 67.8 66
21 patients had
treatment
setting not
documented
and were
excluded
Validation
mATS 94% sensitivity, 93% specificity, 49% PPV,
99.5% NPV, 93% overall accuracy
BTS I 46% sensitivity, 87% specificity, 20% PPV,
96% NPV, 85% overall accuracy
BTS II 53% sensitivity, 83% specificity, 19% PPV,
96% NPV, 81% overall accuracy
mBTS 51% sensitivity, 80% specificity, 16% PPV,
96% NPV, 78% overall accuracy
Myint et al.
2006 [24] SOAR 195 patients
77
(median) 57 None
Derivation:
SOAR (≥2): 81.0% sensitivity, 59.3% specificity,
27.0% PPV, 94.4% NPV
CURB (≥2): 81.5% sensitivity, 61.1% specificity,
25.9% PPV, 95.2% NPV
CURB-65 (≥3): 81.5% sensitivity, 64.2% specificity,
27.5% PPV, 95.4% NPV
CRB-65 (≥2): 85.2% sensitivity, 57.0% specificity,
24.5% PPV, 95.9% NPV
8 BioMed Research International
Table 3: Continued.
Paper Score Patients Age % male Lost to followup Results
Myint et al.
2007 [27]
(derivation)
CURB age 189 patients 75(median) 56.1 None
Derivation:
CURB age: 81.5% sensitivity, 74.1% specificity,
34.4% PPV, 96% NPV
CURB-65: 81.5% sensitivity, 64.2% specificity,
27.5% PPV, 95.4% NPV
Escobar et
al. 2008 [25]
Abbreviated
Fine Score
11030 and 6147
patients 71.3 51.2 None
Derivation:
AFFS: area ROC: inhospital mortality: 0.74 and
30-day mortality: 0.75
Shindo et al.
2008 [26] A-DROP 371 patients 75 59.9 42 (lack data)
Validation:
A-DROP: Area ROC 0.846 (0.790–0.903)
CURB-65: Area ROC 0.835 (0.763–0.908)
Myint et al.
2009 [7, 31]
(validation)
CURB-age 190 patients 76(median) 53 None
Validation full cohort:
CURB age: 50.0% sensitivity, 80.1% specificity,
50.0% PPV, 80.1% NPV
CURB-65: 59.3% sensitivity, 75.7% specificity,
49.2% PPV, 82.4% NPV
Validation for the elderly (>65 years):
CURB age: 54.0% sensitivity, 70.6% specificity,
51.9% PPV, 72.3% NPV
CURB-65: 64.0% sensitivity, 65.9% specificity,
52.5% PPV, 75.7% NPV
Myint et al.
2009 [7, 31]
(derivation)
CURSI,
CURASI 118
75
(median) 51.7 None
Only 1 patient died during hospital stay and the
patient was scored severe by CURSI, CURASI,
and CURB-65
Rello et al.
2009 [28] PIRO score 529 patients NA NA None
Derivation:
PIRO: 86% sensitivity, 79% specificity, 61% PPV,
93% NPV, area ROC 0.88
Liapikou et
al. 2009 [6]
IDSA/ATS
2007 2391 patients 66.7 61.4 289 missing data
Validation:
ATS 2001: 58% sensitivity, 88% specificity
Uchiyama et
al. 2010 [29] PARB 243 patients NA NA None
Derivation:
PARB: 36% sensitivity, 99% specificity, area ROC
0.8705, accuracy 91.9%
Myint et al.
2010 [30]
(validation)
CURSI,
CURASI 190 patients
76
(median) 53 None
Validation full cohort:
CURSI: 61.1% sensitivity, 72.1% specificity, 46.5%
PPV, 82.4% NPV
CURASI: 59.3% sensitivity, 72.8% specificity,
46.4% PPV, 81.8% NPV
CURB-65: 59.3% sensitivity, 75.7% specificity,
49.2% PPV, 82.4% NPV
Validation for the elderly (>65 years):
CURSI: 62.0% sensitivity, 69.4% specificity, 54.4%
PPV, 75.6% NPV
CURASI: 60.0% sensitivity, 70.6% specificity,
54.5% PPV, 75.0% NPV
CURB-65: 64.0% sensitivity, 65.9% specificity,
52.5% PPV, 75.7% NPV
Musonda et
al. 2011 [32]
CARSI,
CARASI 190 patients
76
(median) 53 None
Derivation:
CARSI: 40.7% sensitivity, 87.5% specificity, 56.4%
PPV, 78.8% NPV, 0.641 area ROC
CARASI: 38.9% sensitivity, 89.0% specificity,
58.3% PPV, 78.6% NPV, 0.639 area ROC
CURB-65: 59.3% sensitivity, 75.7% specificity,
49.2% PPV, 82.4% NPV, 0.675 area ROC
URB: urea, respiratory rate, blood pressure; CRB: confusion, respiratory rate, blood pressure; COUW: confusion, oxygen, urea, white cell count; PPV: positive
predictive value; NPV: negative predictive value.
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Figure 2: Balanced accuracy and area under ROC of pneumonia severity scores versus number of variables.
Se
ns
iti
vi
ty
Sensitivity of pneumonia severity scores as a function of the 
number of variables in the score
CURB65
BTS1
BTS2
MRI
mATS
CURB-age
CURSI
CURASI
PIROSOAR
CARSI
CARASI
BTS3
CRB65
CURB65
CRB65
CURB
ATS 2001
PARB
PSI
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 5 10 15 20
Number of variables in score
Studies
Meta-analysis
(a)
0
0.2
0.4
0.6
0.8
1
1.2
Sp
ec
ifi
ci
ty
Specificity of pneumonia severity scores as a function of the 
number of variables in the score
PSI
MRIATS 2001
PIROCURASI
CARASI
CURB65
mATS
CURB-age
CURSI
SOAR
CARSI
PARB
BTS1
BTS2
BTS3
CRB65
CRB65
CURB
0 5 10 15 20
Number of variables in score
Studies
Meta-analysis
(b)
Figure 3: Sensitivity and specificity of pneumonia severity scores by a number of variables.
best balanced accuracies, and this is similarly reflected in the
AUROC. Similarly, Figure 3 shows that PSI had amongst the
highest sensitivity, but the tradeoff is apparent here in the lack
of specificity for PSI as compared to other validated models
such as CURB-65. We also conducted a subgroup analysis
restricted to prospective studies as thesemay be of potentially
higher validity than retrospective datasets (Supplementary
Material 5).
4. Discussion
Our review systematically evaluates and summarizes 20 risk
prediction models for mortality prediction which included
variables required for score calculation in patients with
pneumonia so that clinicians and policy makers (such as
guideline committees and health services researchers) can
make informed choices about the ease of use and comparative
predictive ability. In these times of uncertainty in the health
economy, the number and type of variables required for cal-
culation need to be weighted up against the outright perfor-
mance. Here, the ease of implementation, efficient resource
utilization, and availability/simplicity of testing within
healthcare setting (e.g., community centre, or emergency
department, or intensive care unit) may represent influential
factors in determining the suitability of a particular model.
We found that most of the publishedmodels (irrespective
of complexity) yielded fairly similar performance with regard
to balanced accuracy and AUC. While there may be some
statistical differences in AUC, this may only have limited
consequence when clinicians are making treatment decisions
in individual patients. For instance, in Chalmer’s meta-
analysis, the respective AUCs indicate that the probability
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of PSI correctly discriminating between patients of differing
severity was 0.82, whilst the corresponding figure for CURB-
65 was 0.79. We have deliberately chosen to emphasize
overall performance here with balanced accuracy or AUROC
because while certain models may have demonstrably supe-
rior sensitivity, others had better specificity, thus illustrat-
ing the inevitable trade-off effect between sensitivity and
specificity. The choice of appropriate model will therefore
depend on whether healthcare teams place greater weight on
sensitivity or specificity. Given the small differences between
certain scoring systems, clinicians may equally prefer to
either pragmatically adopt the simplest model (appropriate
to their healthcare setting) or opt for the best established and
widely validated systems.
We presented both results for balanced accuracy and
ROC in order to allow the comparison of the performance of
each score. Balanced accuracy considers both the predictive
value of sensitivity and specificity. While the ROC is a better
measurement of predictive value than balanced accuracy,
several studies reported sensitivity and specificity rather than
ROC.
Themajority of the studies were evaluated in hospital set-
tings, but one study included both inpatients and outpatients
and two studies were conducted in intensive care settings.
The PSI was studied in both inpatient and outpatient settings
which has an advantage because its findings can be generalis-
able to both of these settings [11]. Two studies, mortality risk
index [14] and PIRO score [28], were conducted in intensive
care settings. Community-based studies should be conducted
in the future to include patients with less severe pneumonia.
Our systematic review also identified some key gaps in
the existing research. One particular issue is the lack of
validation data for several models. Given the diversity of
patient populations and the heterogeneity seen in the meta-
analyses of PSI and CURB-65, there is no guarantee that a
model that performs well in one setting will do equally well
in a different setting. It would be very helpful if the profusion
of recently proposed models (often based only on data from
a single centre) could be compared directly against older
versions in a large multicentre international cohort.
The existing studies do not report on acceptability,
uptake, and clinical impact of risk prediction tool in the
routine clinical management of patients with pneumonia.
Perry et al. conducted a survey of emergency physicians’
requirements for clinical decisions rule for acute respiratory
illnesses [33], and they found that physicians wanted a
highly sensitive rule with a median of 97.0% for respiratory
conditions. The most sensitive tool here is PSI, which offers
up to 90% sensitivity to help identify those at higher risk of
death, but physicians in busy emergency departments may
possibly find it too time-consuming and difficult to collect all
of the variables (including detailed past medical history) for
calculating the PSI. Hence, it appears fromPerry’s survey that
there is a need for a score that is highly sensitive beyond what
is currently available from any of the existing scoring systems.
If the uptake and implementation of risk prediction tools in
clinical decision are highly variable [34–37], then patients
are unlikely to reap benefits from the current profusion of
risk predictions tools. There is evidence to suggest that for
the pneumonia severity index the uptake of this score and
the scoring accuracy were low [38, 39]. Equally, it could be
argued that the benefits of risk predictionmodels in reducing
pneumoniamorbidity andmortality need to be demonstrated
in randomized controlled trials.
While the performance of a prediction rule is a major
criterion for comparative superiority, simplicity is a very
important determinant of potential clinical application. A
survey conducted in Australia found that only 12% of respi-
ratory physicians and 35% of emergency physicians reported
using the PSI always or frequently even though it is rec-
ommended by the AustralasianTherapeutic Guidelines [40].
Moreover, this study found that the majority of physicians
were unable to accurately approximate the PSI scores and
calculations of the simpler CURB-65 were more accurate
[40]. This study concluded that it is recommended that a
single, simple pneumonia severity score should be used in
the assessment of CAP [40]. With the computer assisted
programmes, PSI can be calculated easily and accurately. The
pragmatic approach would be to use more complex scoring
with high accuracy in resource-rich settings and to use
alternative simpler scoring system in community or resource-
poor settings. Our systematic review provides comprehensive
comparison for clinicians to use any or a combination of
scores of their choice in various health care settings.
Our review has a number of strengths. We conducted a
systematic search to cover all scores including those that are
established as well as those that have yet to be validated. Also,
there was no restriction of the country of score origin and we
were able to capture the scores from around the world. Our
review also has a number of limitations, including difficulty
in finding exact search terms to pick up this type of study.
Weonly included initial derivation and first validation studies
for the scores identified. Some of the scoring systems do not
appear to have been validated yet. Here, there is a definite
possibility of publication bias where studies showing themost
favorable predictive ability were likely to be accepted for
publication sooner than equivocal or less impressive data. In
order to reduce the possibility of such bias, we were able to
include two systematic reviews [12, 13] that examined the PSI
and CURB scores (CRB-65, CURB, and CURB-65).
Since there already exist established models (CRB-65,
CURB-65, and PSI) with reasonable to good discriminative
ability across a wide range of settings and only small incre-
mental differences between these and newer scores, further
research should mainly focus on why patients get misclassi-
fied and whether we can identify important variables within
them to improve sensitivity of current models. Equally, the
uptake of risk prediction models in routine clinical practice
and any relationship with improved patient outcomes need to
be rigorously assessed, perhaps through cluster-randomized
controlled trials of different care pathways.These future trials
should test if clinical decisions based on pneumonia scores
are associatedwith better patient outcomes compared clinical
decisions based on clinical judgment. Scores should also be
tested in developing countries as pneumoniamortality is high
in the regions. Eventually, the goal should be to clarify the
entire pathway for community-acquired pneumoniamanage-
ment and the role of risk prediction models for each stage
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in the community, at the emergency department, on hospital
wards, and in intensive care.
5. Conclusions
Although there are a multitude of proposed risk prediction
models, few have undergone proper validation, and no
convincing evidence exists that the overall discriminative
ability improves upon the well-established CURB-65 and PSI
models. Future research should thus focus on randomized
trials to test if clinical decision rules using existing risk pre-
diction models and guided treatment pathways can signifi-
cantly improve pneumonia outcomes.
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